The present disclosure is directed to a method of producing nitric oxide comprising (i) providing a composition comprising a metal-organic framework, and (ii) exposing the composition to a nitric oxide-releasing compound. The disclosure also is directed to compositions, coatings, and medical devices
The present disclosure is directed to a method of producing nitric oxide comprising (i) providing a composition comprising a metal-organic framework, and (ii) exposing the composition to a nitric oxide-releasing compound. The disclosure also is directed to compositions, coatings, and medical devices comprising a metal-organic framework.
대표청구항▼
1. A method of producing nitric oxide comprising: providing a composition comprising a three-dimensional metal-organic framework; exposing the composition to physiological fluid including a nitric-oxide-releasing compound; and continuously producing nitric oxide from the nitric oxide releasing compo
1. A method of producing nitric oxide comprising: providing a composition comprising a three-dimensional metal-organic framework; exposing the composition to physiological fluid including a nitric-oxide-releasing compound; and continuously producing nitric oxide from the nitric oxide releasing compound via a catalytic reaction catalyzed by the three-dimensional metal-organic framework, wherein the metal-organic framework comprises Cu3(1,3,5-benzenetricarboxylic acid)2. 2. The method of claim 1, wherein the metal-organic framework has a porous structure. 3. The method of claim 1, wherein the metal-organic framework has a porous structure comprising pores having an average size of about 5 Å to about 500 Å in diameter. 4. The method of claim 1, wherein the nitric oxide-releasing compound comprises a functional group selected from the group consisting of S-nitrosothiol, diazeniumdiolate, nitrate, nitrite, nitroso, and nitrosyl. 5. The method of claim 1, wherein the exposing step comprises contacting the composition with fluids, tissues, or cells. 6. The method of claim 1, wherein the exposing step comprises contacting the composition with blood. 7. The method of claim 1, wherein the nitric oxide-releasing compound is present in fluids, tissues, or cells. 8. The method of claim 1, wherein the nitric oxide-releasing compound is present in blood. 9. The method of claim 1, wherein the composition comprises a therapeutic agent. 10. The method of claim 1, wherein the composition comprises a therapeutic agent selected from the group consisting of anti-thrombotic agents and antimicrobial agents. 11. The method of claim 1, wherein the composition comprises a polymer. 12. The method of claim 1, wherein the composition comprises a polymer selected from the group consisting of polyurethane (PU), polyesters, polyethers, silicones, silicates, poly(vinyl chloride) (PVC), acrylates, methacylates, dextran, synthetic rubber (cis-polyisoprene), polyvinyl acetate, Bakelite, polychloroprene (neoprene), nylon, polystyrene, polyethylene, polypropylene, polyacrylonitrile, polyvinyl butyral (PVB), poly(vinylidene chloride), fluorinated polymers, polytetrafluoroethylene (PTFE), and mixtures and copolymers thereof. 13. The method of claim 1 further comprising administering the composition in a sufficient amount to a patient to treat a disease, disorder or condition. 14. The method of claim 1, further comprising administering the composition in a sufficient amount to a patient in need thereof to treat a disease, disorder, or condition selected from the group consisting of tumors, local infection, systemic infection, macrophage formation, heart disease, artery and vein damage or disease, tissue injury, vascular legions, initimal hyperplasia, heart failure, high or elevated blood pressure, vasoconstriction, platelet adhesion, platelet aggregation, atherosclerosis, thrombo-embolism, thrombosis, smooth muscle cell proliferation, sepsis, complications with medical devices, wounds caused by incisions or insertion of medical devices, cicatrices, endothelial cell damage, arrhythmias, heart defects, congenital heart defects, cell overgrowth, and soft bones. 15. The method of claim 1, wherein the composition produces nitric oxide at catalytic sites on the metal-organic framework for at least 7 days. 16. The method of claim 1, further comprising administering the composition in a sufficient amount to a patient to treat biofouling.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (6)
Yaghi Omar M. (Phoenix AZ), Crystalline metal-organic microporous materials.
Fitzhugh, Anthony L.; Cheng, Peiwen; Saavedra, Joseph; Cafferata, Robert; Hendriks, Marc; Keefer, Larry K.; Tedeschi, Eugene; Verhoeven, Michel I. P. M., Nitric oxide-releasing metallic medical devices.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.